Andrea Boutros Chiara Schiavi Federica Cecchi Francesco Spagnolo Antonio Guadagno Enrica Teresa Tanda Francesca Giusti Giuseppe Murdaca Paola Queirolo
10.3389/fimmu.2020.579523
Front Immunol
2020 Nov 17;11:579523.
braf and mek targeted therapy dabrafenib and trametinib immune-related adverse event irae immunotherapy melanoma sarcoidosis tattoo uveitis
CC BY
https://pubmed.ncbi.nlm.nih.gov/33312171/
Antineoplastic Combined Chemotherapy Protocols / adverse effects Imidazoles / adverse effects Melanoma / drug therapy Oximes / adverse effects Pyridones / adverse effects Pyrimidinones / adverse effects Sarcoidosis / diagnosis Skin Neoplasms / drug therapy
Antineoplastic Combined Chemotherapy Protocols / adverse effects Imidazoles / adverse effects Melanoma / drug therapy Oximes / adverse effects Pyridones / adverse effects Pyrimidinones / adverse effects Sarcoidosis / diagnosis Skin Neoplasms / drug therapy Case Reports Adrenal Cortex Hormones / administration & dosage Adult Antineoplastic Combined Chemotherapy Protocols / therapeutic use Drug-Related Side Effects and Adverse Reactions Female Humans Imidazoles / therapeutic use MAP Kinase Kinase Kinases / genetics Melanoma / complications Mutation / genetics Neoplasm Staging Oximes / therapeutic use Proto-Oncogene Proteins B-raf / genetics Proto-Oncogene Proteins B-raf / metabolism Pyridones / therapeutic use Pyrimidinones / therapeutic use Sarcoidosis / etiology Sarcoidosis / prevention & control Skin Neoplasms / complications Adrenal Cortex Hormones Imidazoles Oximes Pyridones Pyrimidinones trametinib Proto-Oncogene Proteins B-raf MAP Kinase Kinase Kinases dabrafenib
PMC7704616
33312171
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
2020